World’s First MAGE-A4-Targeting TCR-NK Therapy Zelluna Doses First Patient in Clinical Trial
Zelluna ASA, a Norwegian biotech company pioneering allogeneic cell therapies for solid cancers, recently announced that the first patient has received the first dose of ZI-MA4-1 in the ZIMA-101 Phase 1 clinical trial. The treatment was administered at The Christie NHS Foundation Trust in Manchester,…
When Synovial Sarcoma Mimics the Heart’s Most Common Tumor
A case report in AME Case Reports by Yun Xiao, Zhourui Liu, and Sha Li of the Department of Ultrasound at Guizhou Medical University, China, documents a rare case of synovial sarcoma arising directly in the pulmonary artery, a location so uncommon that it was…
Closing the AYA Gap: Clinical Trials, Genetic Testing, and Palliative Care for Young Sarcoma Patients
A new educational review in the American Society of Clinical Oncology Educational Book, authored by Sophie Jessop, MBBS, and colleagues, examines three persistent gaps in care for adolescents and young adults (AYAs) with sarcoma: clinical trial access, genetic testing for inherited cancer risk, and timely…
The Synovial Sarcoma Foundation Surpasses $2 Million in Research Funding
Thanks to the generosity of donors and supporters, the Fund has now raised over $2 million, accelerating research initiatives at…
First-Ever Synovial Sarcoma Conference to Bring Together Patients, Researchers, and Experts in a Landmark Event
PHILADELPHIA, PA, UNITED STATES, February 20, 2025 — The Synovial Sarcoma Foundation is proud to announce that Children’s Hospital of Philadelphia…
Synovial Sarcoma Registry Reaches New Milestone
The Synovial Sarcoma Registry, launched in partnership with the Children’s Hospital of Philadelphia (CHOP), continues to grow as a critical…
Black Flag Sarcoma Race Team Takes the Track for Awareness
The Black Flag Sarcoma Race Team is shifting into high gear, using motorsports as a platform to raise awareness for…
Synovial Sarcoma Tumor Board Gains Widespread Adoption
The Synovial Sarcoma Tumor Board, funded by the Spence Family Synovial Sarcoma Foundation, has become an essential collaborative hub for…
Teresa Belluco: A Legacy of Hope and Impact
Teresa Belluco was just 13 years old when she received a devastating diagnosis—synovial sarcoma, a rare and aggressive cancer that…
